LAVA Therapeutics (LVTX)
(Delayed Data from NSDQ)
$1.79 USD
-0.12 (-6.28%)
Updated Jul 11, 2024 04:00 PM ET
After-Market: $1.78 -0.01 (-0.56%) 7:58 PM ET
2-Buy of 5 2
C Value F Growth A Momentum D VGM
Price, Consensus and EPS Surprise
LVTX 1.79 -0.12(-6.28%)
Will LVTX be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for LVTX based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for LVTX
Eton Pharmaceuticals, Inc. (ETON) Reports Q4 Loss, Lags Revenue Estimates
LAVA Therapeutics N.V. (LVTX) Reports Q2 Loss, Tops Revenue Estimates
LVTX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Aravive (ARAV) Reports Q2 Loss, Tops Revenue Estimates
Evogene (EVGN) Reports Q2 Loss, Lags Revenue Estimates
Lava (LVTX) Discontinues Hematological Tumor Study, Shares Fall
Other News for LVTX
LAVA Therapeutics: Promising Clinical Trials and Strategic Partnerships Underpin Buy Rating
LAVA Therapeutics to Participate in the H.C. Wainwright 2nd Annual Immune Cell Engager Virtual Conference
LAVA Therapeutics Shareholders Approve Key Resolutions
LAVA Announces Annual Meeting of Shareholders
LAVA Therapeutics’ Innovative Gammabody® Cancer Therapy